{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:58:19Z","timestamp":1794502699845,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["HR21-848"],"award-info":[{"award-number":["HR21-848"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundacao para a ciencia e tecnologia","award":["SFRH\/BD\/144817\/2019"],"award-info":[{"award-number":["SFRH\/BD\/144817\/2019"]}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101080744"],"award-info":[{"award-number":["101080744"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The malaria vaccination landscape has seen significant advancements with the recent endorsement of RTS,S\/AS01 and R21\/Matrix-M vaccines, which target the pre-erythrocytic stages of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (Pf) infection. However, several challenges remain to be addressed, including the incomplete protection afforded by these vaccines, their dependence on a single Pf antigen, and the fact that they were not designed to protect against\n                    <jats:italic>P. vivax<\/jats:italic>\n                    (Pv) malaria. Injectable formulations of whole-sporozoite (WSpz) malaria vaccines offer a promising alternative to existing subunit vaccines, with recent developments including genetically engineered parasites and optimized administration regimens. Clinical evaluations demonstrate varying efficacy, influenced by factors, such as immune status, prior exposure to malaria, and age. Despite significant progress, a few hurdles persist in vaccine production, deployment, and efficacy in malaria-endemic regions, particularly in children. Concurrently, transgenic parasites expressing Pv antigens emerge as potential solutions for PvWSpz vaccine development. Ongoing clinical studies and advancements in vaccine technology, including the recently described PfSPZ-LARC2 candidate, signify a hopeful future for WSpz malaria vaccines, which hold great promise in the global fight against malaria.\n                  <\/jats:p>","DOI":"10.1038\/s44321-024-00131-0","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:04:19Z","timestamp":1726495459000},"page":"2279-2289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Whole-sporozoite malaria vaccines: where we are, where we are going"],"prefix":"10.1038","volume":"16","author":[{"given":"Diana","family":"Moita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-6029","authenticated-orcid":false,"given":"Miguel","family":"Prud\u00eancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"131_CR1","doi-asserted-by":"publisher","unstructured":"Arisue N, Palacpac NMQ (2024) Asymptomatic parasitemia and RTS,S vaccine efficacy. Lancet Infect Dis https:\/\/doi.org\/10.1016\/S1473-3099(24)00214-7","DOI":"10.1016\/S1473-3099(24)00214-7"},{"key":"131_CR2","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/S0140-6736(24)00004-7","volume":"403","author":"KP Asante","year":"2024","unstructured":"Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, Moore KA, Kwambai TK, Hamel MJ, Gyan T, Westercamp N, Kapito-Tembo A, Njuguna P, Ansong D, Kariuki S, Mvalo T, Snell P, Schellenberg D, Welega P, Otieno L et al (2024) Feasibility, safety, and impact of the RTS,S\/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet 403:1660\u20131670","journal-title":"Lancet"},{"key":"131_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2456-5","volume":"17","author":"M Bermudez","year":"2018","unstructured":"Bermudez M, Moreno-Perez DA, Arevalo-Pinzon G, Curtidor H, Patarroyo MA (2018) Plasmodium vivax in vitro continuous culture: the spoke in the wheel. Malar J 17:301","journal-title":"Malar J"},{"key":"131_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0626-2","volume":"14","author":"EM Bijker","year":"2015","unstructured":"Bijker EM, Nganou-Makamdop K, van Gemert GJ, Zavala F, Cockburn I, Sauerwein RW (2015) Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria. Malar J 14:130","journal-title":"Malar J"},{"key":"131_CR5","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1016\/S1473-3099(23)00126-3","volume":"23","author":"A Bjorkman","year":"2023","unstructured":"Bjorkman A, Benn CS, Aaby P, Schapira A (2023) RTS,S\/AS01 malaria vaccine-proven safe and effective? Lancet Infect Dis 23:e318\u2013e322","journal-title":"Lancet Infect Dis"},{"key":"131_CR6","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3390\/pathogens11121487","volume":"11","author":"C Bowers","year":"2022","unstructured":"Bowers C, Hancox L, Peissig K, Shiau JC, Vantaux A, Witkowski B, Phal S, Maher SP, Harty JT, Kyle DE, Kurup SP (2022) Cryopreservation of Plasmodium sporozoites. Pathogens 11:1487","journal-title":"Pathogens"},{"key":"131_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","volume":"266","author":"DF Clyde","year":"1973","unstructured":"Clyde DF, Most H, McCarthy VC, Vanderberg JP (1973) Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 266:169\u2013177","journal-title":"Am J Med Sci"},{"key":"131_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101579","volume":"52","author":"D Coulibaly","year":"2022","unstructured":"Coulibaly D, Kone AK, Traore K, Niangaly A, Kouriba B, Arama C, Zeguime A, Dolo A, Lyke KE, Plowe CV, Abebe Y, Potter GE, Kennedy JK, Galbiati SM, Nomicos E, Deye GA, Richie TL, James ER, Kc N, Sim BKL et al (2022) PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: a randomized, controlled phase 1 trial. EClinicalMedicine 52:101579","journal-title":"EClinicalMedicine"},{"key":"131_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/embo-reports\/kve032","volume":"2","author":"AF Cowman","year":"2001","unstructured":"Cowman AF, Duraisingh MT (2001) An old enemy, a new battle plan. Perspective on combating drug-resistant malaria. EMBO Rep 2:77\u201379","journal-title":"EMBO Rep"},{"key":"131_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ouedraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D et al (2024) Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403:533\u2013544","journal-title":"Lancet"},{"key":"131_CR72","doi-asserted-by":"publisher","unstructured":"Diawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, Soumbounou IH, Gaoussou S, Zaidi I, Mahamar A, Attaher O, Fried M, Wylie BJ, Mohan R, Doan V, Doritchamou JYA, Dolo A, Morrison RD, Wang J, Hu Z et al (2024) Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis https:\/\/doi.org\/10.1016\/S1473-3099(24)00360-8","DOI":"10.1016\/S1473-3099(24)00360-8"},{"key":"131_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.mib.2007.07.009","volume":"10","author":"P Druilhe","year":"2007","unstructured":"Druilhe P, Barnwell JW (2007) Pre-erythrocytic stage malaria vaccines: time for a change in path. Curr Opin Microbiol 10:371\u2013378","journal-title":"Curr Opin Microbiol"},{"key":"131_CR12","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1016\/S2214-109X(21)00498-8","volume":"9","author":"J D\u2019Souza","year":"2021","unstructured":"D\u2019Souza J, Nderitu D (2021) Ethical considerations for introducing RTS,S\/AS01 in countries with moderate to high Plasmodium falciparum malaria transmission. Lancet Glob Health 9:e1642\u2013e1643","journal-title":"Lancet Glob Health"},{"key":"131_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, Chakravarty S, Stafford A, Ruck RC, Eappen AG, Li T, Billingsley PF, Manoj A, Silva JC, Moser K, Nielsen R, Tosh D, Cicatelli S, Ganeshan H, Case J et al (2017) Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2:e89154","journal-title":"JCI Insight"},{"key":"131_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG et al (2011) Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334:475\u2013480","journal-title":"Science"},{"key":"131_CR15","unstructured":"Franke-Fayard B (2022) Development and clinical evaluation of genetically attenuated parasite that arrests late in the liver. Oral Presentation Tues, Nov 1, 10:45 AM, 2022 Annual Meeting of the American Society for Tropical Medicine and Hygiene"},{"key":"131_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00558-x","volume":"7","author":"B Franke-Fayard","year":"2022","unstructured":"Franke-Fayard B, Marin-Mogollon C, Geurten FJA, Chevalley-Maurel S, Ramesar J, Kroeze H, Baalbergen E, Wessels E, Baron L, Soulard V, Martinson T, Aleshnick M, Huijs ATG, Subudhi AK, Miyazaki Y, Othman AS, Kolli SK, Lamers OAC, Roques M, Stanway RR et al (2022) Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver. NPJ Vaccines 7:139","journal-title":"NPJ Vaccines"},{"key":"131_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0817-x","volume":"14","author":"GP Gomez-Perez","year":"2015","unstructured":"Gomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, Moncunill G, Campo JJ, Cistero P, Jimenez A, Barrios D, Mordmuller B, Pardos J, Navarro M, Zita CJ, Nhamuave CA, Garcia-Basteiro AL, Sanz A, Aldea M, Manoj A et al (2015) Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J 14:306","journal-title":"Malar J"},{"key":"131_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.135589","volume":"5","author":"D Goswami","year":"2020","unstructured":"Goswami D, Betz W, Locham NK, Parthiban C, Brager C, Schafer C, Camargo N, Nguyen T, Kennedy SY, Murphy SC, Vaughan AM, Kappe SH (2020) A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5:1\u201319","journal-title":"JCI Insight"},{"key":"131_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s44321-024-00057-7","volume":"16","author":"D Goswami","year":"2024","unstructured":"Goswami D, Patel H, Betz W, Armstrong J, Camargo N, Patil A, Chakravarty S, Murphy SC, Sim BKL, Vaughan AM, Hoffman SL, Kappe SH (2024) A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol Med 16:723\u2013754","journal-title":"EMBO Mol Med"},{"key":"131_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Chattopadhyay R, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV et al (2010) Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6:97\u2013106","journal-title":"Hum Vaccin"},{"key":"131_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.851028","volume":"13","author":"ER James","year":"2022","unstructured":"James ER, Matheny S, Overby J, Sim BKL, Eappen AG, Li T, Li ML, Richie TL, Chakravarty S, Gunasekera A, Murshedkar T, Billingsley PF, Hoffman SL (2022) A first for human vaccinology: GMP compliant radiation attenuation of Plasmodium falciparum sporozoites for production of a vaccine against malaria. Front Immunol 13:851028","journal-title":"Front Immunol"},{"key":"131_CR22","doi-asserted-by":"publisher","first-page":"e5075","DOI":"10.1371\/journal.pone.0005075","volume":"4","author":"O Jobe","year":"2009","unstructured":"Jobe O, Donofrio G, Sun G, Liepinsh D, Schwenk R, Krzych U (2009) Immunization with radiation-attenuated Plasmodium berghei sporozoites induces liver cCD8alpha+DC that activate CD8+T cells against liver-stage malaria. PLoS ONE 4:e5075","journal-title":"PLoS ONE"},{"key":"131_CR23","doi-asserted-by":"publisher","first-page":"e169060","DOI":"10.1172\/JCI169060","volume":"134","author":"S Jongo","year":"2024","unstructured":"Jongo S, Church LWP, Milando F, Qassim M, Schindler T, Rashid M, Tumbo A, Nyaulingo G, Bakari BM, Athuman Mbaga T, Mohamed L, Kassimu K, Simon BS, Mpina M, Zaidi I, Duffy PE, Swanson 2nd PA, Seder R, Herman JD, Mendu M et al (2024) Safety and protective efficacy of PfSPZ vaccine administered to HIV-negative and -positive Tanzanian adults. J Clin Investig 134:e169060","journal-title":"J Clin Investig"},{"key":"131_CR24","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo SA, Church LWP, Mtoro AT, Schindler T, Chakravarty S, Ruben AJ, Swanson PA, Kassim KR, Mpina M, Tumbo AM, Milando FA, Qassim M, Juma OA, Bakari BM, Simon B, James ER, Abebe Y, Kc N, Saverino E, Fink M et al (2020) Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults. Clin Infect Dis 71:2849\u20132857","journal-title":"Clin Infect Dis"},{"key":"131_CR25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, Rutishauser T, Rothen J, Tumbo A, Mkindi C, Mpina M, Mtoro AT, Ishizuka AS, Kassim KR, Milando FA, Qassim M, Juma OA, Mwakasungula S, Simon B, James ER et al (2018) Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg 99:338\u2013349","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"131_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1473-3099(24)00179-8","volume":"24","author":"M Juraska","year":"2024","unstructured":"Juraska M, Early AM, Li L, Schaffner SF, Lievens M, Khorgade A, Simpkins B, Hejazi NS, Benkeser D, Wang Q, Mercer LD, Adjei S, Agbenyega T, Anderson S, Ansong D, Bii DK, Buabeng PBY, English S, Fitzgerald N, Grimsby J et al (2024) Genotypic analysis of RTS,S\/AS01(E) malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial. Lancet Infect Dis 24(9):1025\u20131036","journal-title":"Lancet Infect Dis"},{"key":"131_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.copbio.2012.04.003","volume":"23","author":"SM Khan","year":"2012","unstructured":"Khan SM, Janse CJ, Kappe SH, Mikolajczak SA (2012) Genetic engineering of attenuated malaria parasites for vaccination. Curr Opin Biotechnol 23:908\u2013916","journal-title":"Curr Opin Biotechnol"},{"key":"131_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aad9099","volume":"9","author":"JG Kublin","year":"2017","unstructured":"Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH (2017) Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med 9:1\u201311","journal-title":"Sci Transl Med"},{"key":"131_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1144453","volume":"14","author":"S Kumari","year":"2023","unstructured":"Kumari S, Sinha A (2023) Culture and transfection: two major bottlenecks in understanding Plasmodium vivax biology. Front Microbiol 14:1144453","journal-title":"Front Microbiol"},{"key":"131_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens MB (2020) RTS,S\/AS01 vaccine (Mosquirix): an overview. Hum Vaccin Immunother 16:480\u2013489","journal-title":"Hum Vaccin Immunother"},{"key":"131_CR31","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1242\/jeb.00644","volume":"206","author":"TC Luke","year":"2003","unstructured":"Luke TC, Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 206:3803\u20133808","journal-title":"J Exp Biol"},{"key":"131_CR32","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke KE, Singer A, Berry AA, Reyes S, Chakravarty S, James ER, Billingsley PF, Gunasekera A, Manoj A, Murshedkar T, Laurens MB, Church WP, Garver Baldwin LS, Sedegah M, Banania G, Ganeshan H, Guzman I, Reyes A, Wong M, Belmonte A et al (2021) Multidose priming and delayed boosting improve Plasmodium falciparum sporozoite vaccine efficacy against heterologous P. falciparum controlled human malaria infection. Clin Infect Dis 73:e2424\u2013e2435","journal-title":"Clin Infect Dis"},{"key":"131_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0068-2","volume":"3","author":"AM Mendes","year":"2018","unstructured":"Mendes AM, Machado M, Goncalves-Rosa N, Reuling IJ, Foquet L, Marques C, Salman AM, Yang ASP, Moser KA, Dwivedi A, Hermsen CC, Jimenez-Diaz B, Viera S, Santos JM, Albuquerque I, Bhatia SN, Bial J, Angulo-Barturen I, Silva JC, Leroux-Roels G et al (2018a) A Plasmodium berghei sporozoite-based vaccination platform against human malaria. NPJ Vaccines 3:33","journal-title":"NPJ Vaccines"},{"key":"131_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0091-3","volume":"3","author":"AM Mendes","year":"2018","unstructured":"Mendes AM, Reuling IJ, Andrade CM, Otto TD, Machado M, Teixeira F, Pissarra J, Goncalves-Rosa N, Bonaparte D, Sinfronio J, Sanders M, Janse CJ, Khan SM, Newbold CI, Berriman M, Lee CK, Wu Y, Ockenhouse CF, Sauerwein RW, Prudencio M (2018b) Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate. NPJ Vaccines 3:54","journal-title":"NPJ Vaccines"},{"key":"131_CR35","doi-asserted-by":"crossref","unstructured":"Mendes AM, Scholzen A, Mueller A-K, Shahid M. Khan, Sauerwein RW, Prud\u00eancio M (2017) Whole-sporozoite malaria vaccines. In: Mota MM, Rodriguez A (eds) Malaria. Springer, Cham, Switzerland 100\u2013124","DOI":"10.1007\/978-3-319-45210-4_6"},{"key":"131_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.591046","volume":"10","author":"Y Miyazaki","year":"2020","unstructured":"Miyazaki Y, Marin-Mogollon C, Imai T, Mendes AM, van der Laak R, Sturm A, Geurten FJA, Miyazaki S, Chevalley-Maurel S, Ramesar J, Kolli SK, Kroeze H, van Schuijlenburg R, Salman AM, Wilder BK, Reyes-Sandoval A, Dechering KJ, Prudencio M, Janse CJ, Khan SM et al (2020) Generation of a genetically modified chimeric Plasmodium falciparum parasite expressing Plasmodium vivax circumsporozoite protein for malaria vaccine development. Front Cell Infect Microbiol 10:591046","journal-title":"Front Cell Infect Microbiol"},{"key":"131_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00585-8","volume":"7","author":"D Moita","year":"2022","unstructured":"Moita D, Maia TG, Duarte M, Andrade CM, Albuquerque IS, Dwivedi A, Silva JC, Gonzalez-Ceron L, Janse CJ, Mendes AM, Prudencio M (2022a) A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria. NPJ Vaccines 7:163","journal-title":"NPJ Vaccines"},{"key":"131_CR38","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1111\/febs.16016","volume":"289","author":"D Moita","year":"2022","unstructured":"Moita D, Nunes-Cabaco H, Mendes AM, Prudencio M (2022b) A guide to investigating immune responses elicited by whole-sporozoite pre-erythrocytic vaccines against malaria. FEBS J 289:3335\u20133359","journal-title":"FEBS J"},{"key":"131_CR39","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1016\/j.vaccine.2023.11.023","volume":"41","author":"D Moita","year":"2023","unstructured":"Moita D, Nunes-Cabaco H, Rola C, Franke-Fayard B, Janse CJ, Mendes AM, Prudencio M (2023a) Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines. Vaccine 41:7618\u20137625","journal-title":"Vaccine"},{"key":"131_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s44321-024-00056-8","volume":"16","author":"D Moita","year":"2024","unstructured":"Moita D, Prudencio M (2024) A new malaria vaccination tool based on replication-competent Plasmodium falciparum parasites. EMBO Mol Med 16:667\u2013669","journal-title":"EMBO Mol Med"},{"key":"131_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00778-9","volume":"8","author":"D Moita","year":"2023","unstructured":"Moita D, Rola C, Nunes-Cabaco H, Nogueira G, Maia TG, Othman AS, Franke-Fayard B, Janse CJ, Mendes AM, Prudencio M (2023b) The effect of dosage on the protective efficacy of whole-sporozoite formulations for immunization against malaria. NPJ Vaccines 8:182","journal-title":"NPJ Vaccines"},{"key":"131_CR42","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/S0140-6736(21)01065-5","volume":"397","author":"V Moorthy","year":"2021","unstructured":"Moorthy V, Binka F (2021) R21\/Matrix-M: a second malaria vaccine? Lancet 397:1782\u20131783","journal-title":"Lancet"},{"key":"131_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00510-z","volume":"7","author":"B Mordmuller","year":"2022","unstructured":"Mordmuller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, Bayon PG, Esen M, Gmeiner M, Held J, Heimann HL, Woldearegai TG, Ibanez J, Flugge J, Fendel R, Kreidenweiss A, Kc N, Murshedkar T, Chakravarty S, Riyahi P et al (2022) A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines 7:100","journal-title":"NPJ Vaccines"},{"key":"131_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordmuller","year":"2017","unstructured":"Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, Gmeiner M, Campo JJ, Esen M, Ruben AJ, Held J, Calle CL, Mengue JB, Gebru T, Ibanez J, Sulyok M, James ER, Billingsley PF, Natasha KC, Manoj A et al (2017) Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542:445\u2013449","journal-title":"Nature"},{"key":"131_CR45","doi-asserted-by":"publisher","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy SC, Deye GA, Sim BKL, Galbiati S, Kennedy JK, Cohen KW, Chakravarty S, Kc N, Abebe Y, James ER, Kublin JG, Hoffman SL, Richie TL, Jackson LA (2021) PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: a randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog 17:e1009594","journal-title":"PLoS Pathog"},{"key":"131_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari A, Healy SA, Lane J, Cook DM, Kalhori S, Wyatt C, Kolluri A, Marte-Salcedo O, Imeru A, Nason M, Ding LK, Decederfelt H, Duan J, Neal J, Raiten J, Lee G, Hume JCC, Jeon JE, Ikpeama I, Kc N et al (2021) Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595:289\u2013294","journal-title":"Nature"},{"key":"131_CR47","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji ST, Aide P, Anderson S, Ansong D, Aponte JJ, Asante KP, Bejon P, Birkett AJ, Bruls M, Connolly KM et al (2015) Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. New Engl J Med 373:2025\u20132037","journal-title":"New Engl J Med"},{"key":"131_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.977472","volume":"13","author":"H Nunes-Cabaco","year":"2022","unstructured":"Nunes-Cabaco H, Moita D, Prudencio M (2022) Five decades of clinical assessment of whole-sporozoite malaria vaccines. Front Immunol 13:977472","journal-title":"Front Immunol"},{"key":"131_CR49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/216160a0","volume":"216","author":"RS Nussenzweig","year":"1967","unstructured":"Nussenzweig RS, Vanderberg J, Most H, Orton C (1967) Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216:160\u2013162","journal-title":"Nature"},{"key":"131_CR50","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, Akach D, Sang T, Gutman JR, Nzuu EL, Dungani A, Kim Lee Sim B, Oloo PN, Otieno K, Bii DK, Billingsley PF, James ER, Kariuki S, Samuels AM, Jongo S et al (2021) Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med 27:1636\u20131645","journal-title":"Nat Med"},{"key":"131_CR51","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","volume":"111","author":"S Plotkin","year":"2014","unstructured":"Plotkin S (2014) History of vaccination. Proc Natl Acad Sci USA 111:12283\u201312287","journal-title":"Proc Natl Acad Sci USA"},{"key":"131_CR52","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41564-020-0768-z","volume":"5","author":"M Prudencio","year":"2020","unstructured":"Prudencio M, Costa JC (2020) Research funding after COVID-19. Nat Microbiol 5:986","journal-title":"Nat Microbiol"},{"key":"131_CR53","doi-asserted-by":"publisher","first-page":"e1002198","DOI":"10.1371\/journal.pbio.1002198","volume":"13","author":"AF Read","year":"2015","unstructured":"Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK (2015) Imperfect vaccination can enhance the transmission of highly virulent pathogens. PLoS Biol 13:e1002198","journal-title":"PLoS Biol"},{"key":"131_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aay2578","volume":"12","author":"IJ Reuling","year":"2020","unstructured":"Reuling IJ, Mendes AM, de Jong GM, Fabra-Garcia A, Nunes-Cabaco H, van Gemert GJ, Graumans W, Coffeng LE, de Vlas SJ, Yang ASP, Lee C, Wu Y, Birkett AJ, Ockenhouse CF, Koelewijn R, van Hellemond JJ, van Genderen PJJ, Sauerwein RW, Prudencio M (2020) An open-label phase 1\/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci Transl Med 12:1\u201312","journal-title":"Sci Transl Med"},{"key":"131_CR55","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/14760584.2023.2245890","volume":"22","author":"TL Richie","year":"2023","unstructured":"Richie TL, Church LWP, Murshedkar T, Billingsley PF, James ER, Chen MC, Abebe Y, Natasha K, Chakravarty S, Dolberg D, Healy SA, Diawara H, Sissoko MS, Sagara I, Cook DM, Epstein JE, Mordmuller B, Kapulu M, Kreidenweiss A, Franke-Fayard B et al (2023) Sporozoite immunization: innovative translational science to support the fight against malaria. Expert Rev Vaccines 22:964\u20131007","journal-title":"Expert Rev Vaccines"},{"key":"131_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2012.12-0613","volume":"88","author":"M Roestenberg","year":"2013","unstructured":"Roestenberg M, Bijker EM, Sim BKL, Billingsley PF, James ER, Bastiaens GJH, Teirlinck AC, Scholzen A, Teelen K, Arens T, van der Ven A, Gunasekera A, Chakravarty S, Velmurugan S, Hermsen CC, Sauerwein RW, Hoffman SL (2013) Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 88:5\u201313","journal-title":"Am J Trop Med Hyg"},{"key":"131_CR57","doi-asserted-by":"publisher","first-page":"eaaz5629","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, Manurung M, Yap XZ, Garcia AF, Koopman JPR, Meij P, Wessels E, Teelen K, van Waardenburg YM, van de Vegte-Bolmer M, van Gemert GJ, Visser LG, van der Ven A, de Mast Q, Natasha KC et al (2020a) A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med 12:eaaz5629","journal-title":"Sci Transl Med"},{"key":"131_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg M, Walk J, van der Boor SC, Langenberg MCC, Hoogerwerf MA, Janse JJ, Manurung M, Yap XZ, Garcia AF, Koopman JPR, Meij P, Wessels E, Teelen K, van Waardenburg YM, van de Vegte-Bolmer M, van Gemert GJ, Visser LG, van der Ven A, de Mast Q, Natasha KC et al (2020b) A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci Transl Med 12:1\u201311","journal-title":"Sci Transl Med"},{"key":"131_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2013.09.163","volume":"67","author":"A Ruben","year":"2013","unstructured":"Ruben A, Awe A, Hoffman SL, Sim BK, Billingsley PF, Manoj A, Chakravarty S, Gunasekera A, Stafford R, Li M, James E (2013) Cryopreservation of Plasmodium falciparum sporozoites and Sanaria\u00ae PfSPZ vaccine. Cryobiology 67:1","journal-title":"Cryobiology"},{"key":"131_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00360-1","volume":"6","author":"T Sahu","year":"2021","unstructured":"Sahu T, Gehrke EJ, Flores-Garcia Y, Mlambo G, Romano JD, Coppens I (2021) Chemoprophylaxis vaccination with a Plasmodium liver stage autophagy mutant affords enhanced and long-lasting protection. NPJ Vaccines 6:98","journal-title":"NPJ Vaccines"},{"issue":"5","key":"131_CR61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","volume":"24","author":"N Schmit","year":"2024","unstructured":"Schmit N, Topazian HM, Natama HM, Bellamy D, Traore O, Some MA, Rouamba T, Tahita MC, Bonko MDA, Sourabie A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo MS, Lopez FR, Charles GD, McCain K et al (2024) The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis 24(5):465\u2013475","journal-title":"Lancet Infect Dis"},{"key":"131_CR62","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH et al (2013) Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341:1359\u20131365","journal-title":"Science"},{"key":"131_CR63","first-page":"20143085","volume":"282","author":"AK Simon","year":"2015","unstructured":"Simon AK, Hollander GA, McMichael A (2015) Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 282:20143085","journal-title":"Proc Biol Sci"},{"key":"131_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj3776","volume":"14","author":"SB Sirima","year":"2022","unstructured":"Sirima SB, Ouedraogo A, Tiono AB, Kabore JM, Bougouma EC, Ouattara MS, Kargougou D, Diarra A, Henry N, Ouedraogo IN, Billingsley PF, Manoj A, Abebe Y, Kc N, Ruben A, Richie TL, James ER, Joshi S, Shrestha B, Strauss K et al (2022) A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria. Sci Transl Med 14:eabj3776","journal-title":"Sci Transl Med"},{"key":"131_CR65","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, Kamate B, Samake Y, Guindo MA, Dolo A, Niangaly A, Niare K, Zeguime A, Sissoko K, Diallo H, Thera I, Ding K, Fay MP, O\u2019Connell EM, Nutman TB et al (2017) Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17:498\u2013509","journal-title":"Lancet Infect Dis"},{"key":"131_CR66","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2022","unstructured":"Sissoko MS, Healy SA, Katile A, Zaidi I, Hu Z, Kamate B, Samake Y, Sissoko K, Mwakingwe-Omari A, Lane J, Imeru A, Mohan R, Thera I, Guindo CO, Dolo A, Niare K, Koita F, Niangaly A, Rausch KM, Zeguime A et al (2022) Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect Dis 22:377\u2013389","journal-title":"Lancet Infect Dis"},{"key":"131_CR67","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.pt.2017.07.001","volume":"33","author":"R Thomson-Luque","year":"2017","unstructured":"Thomson-Luque R, Shaw Saliba K, Kocken CHM, Pasini EM (2017) A continuous, long-term Plasmodium vivax in vitro blood-stage culture: what are we missing? Trends Parasitol 33:921\u2013924","journal-title":"Trends Parasitol"},{"key":"131_CR68","doi-asserted-by":"publisher","first-page":"e03582","DOI":"10.7554\/eLife.03582","volume":"3","author":"BC van Schaijk","year":"2014","unstructured":"van Schaijk BC, Ploemen IH, Annoura T, Vos MW, Foquet L, van Gemert GJ, Chevalley-Maurel S, van de Vegte-Bolmer M, Sajid M, Franetich JF, Lorthiois A, Leroux-Roels G, Meuleman P, Hermsen CC, Mazier D, Hoffman SL, Janse CJ, Khan SM, Sauerwein RW (2014) A genetically attenuated malaria vaccine candidate based on P. falciparum b9\/slarp gene-deficient sporozoites. eLife 3:e03582","journal-title":"eLife"},{"key":"131_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.vaccine.2008.10.028","volume":"27","author":"JP Vanderberg","year":"2009","unstructured":"Vanderberg JP (2009) Reflections on early malaria vaccine studies, the first successful human malaria vaccination, and beyond. Vaccine 27:2\u20139","journal-title":"Vaccine"},{"key":"131_CR70","unstructured":"WHO (2024) Malaria vaccines (RTS,S and R21). WHO"},{"key":"131_CR71","doi-asserted-by":"publisher","first-page":"e156588","DOI":"10.1172\/JCI156588","volume":"132","author":"F Zavala","year":"2022","unstructured":"Zavala F (2022) RTS,S: the first malaria vaccine. J Clin Investig 132:e156588","journal-title":"J Clin Investig"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00131-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00131-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00131-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:43:09Z","timestamp":1779064989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00131-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,14]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00131-0","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"12 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}